Search results for "blood coagulation"

showing 10 items of 154 documents

Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding.

2003

Evaluation of liver disease in patients with a high risk of postbiopsy bleeding presents a diagnostic challenge. Mini-laparoscopy offers the possibility of coagulation of biopsy site and the additional advantage of macroscopic liver assessment. We wished to assess the value and safety of mini-laparoscopy with guided biopsy as a diagnostic approach in patients in whom percutaneous liver biopsy is considered contraindicated because of a marked coagulopathy.We investigated 61 consecutive patients with marked coagulopathy (prolonged international normalized ratio1.5, thrombocytopenia50/nl, or both; von Willebrand's disease/hemophilia). Diagnostic mini-laparoscopy with visually guided liver biop…

AdultMalemedicine.medical_specialtyValidation studyAdolescentBiopsyHemorrhageBiopsymedicineCoagulopathyHumansIn patientLaparoscopyChildBiopsy methodsAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryLiver DiseasesMini laparoscopyGastroenterologyInfantReproducibility of ResultsEquipment DesignBlood Coagulation DisordersMiddle Agedmedicine.diseaseLaparoscopesSurgeryEndoscopyChild PreschoolFeasibility StudiesFemaleLaparoscopyRadiologybusinessThe American journal of gastroenterology
researchProduct

Haemocoagulative modifications correlated with pregnancy

2006

The aim of this paper was to establish the physiologic changes in the coagulation and fibrinolytic systems during normal pregnancy.One-hundred and twenty normal pregnant women were investigated in a longitudinal study involving 3 measurements: blood samples were collected at 12, 24 and 36 weeks of gestation and were assayed for prothrombin time, antithrombin III (ATIII) activity, protein C activity, protein S (PS) activity, prothrombin fragments 1+2, type 1 plasminogen activator inhibitor activity, tissue plasminogen activator antigen, plasminogen, activated protein C resistance, factors VII and VIII levels and D dimer. Student t-test, one way analysis of variance (ANOVA) and Fisher test we…

AdultPregnancyFibrinolysisPregnancy Complications HematologicHumansFibrinolysiFemaleLongitudinal StudieLongitudinal StudiesBlood CoagulationHuman
researchProduct

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris

1996

Percutaneous transluminal coronary angioplasty is often complicated by thrombotic abrupt vessel closure in patients with unstable angina pectoris. The present multicentre trial was performed to determine the feasibility of two-dose regimens of recombinant hirudin (r-hirudin) compared to standard heparin in patients undergoing coronary angioplasty for unstable angina, and to investigate the effects of the different treatment regimen on markers of coagulation activation. At five participating centres, 61 patients were randomly enrolled in one of two sequential groups of r-hirudin (group 1: 0.3 mg.kg-1 i.v. bolus, 0.12 mg.kg-1.h-1 i.v. infusion; 21 patients; group 2: 0.5 mg.kg-1 i.v. bolus, 0.…

Adultmedicine.drug_classmedicine.medical_treatmentHirudinEnzyme-Linked Immunosorbent AssayAnginaFibrinolytic AgentsmedicineHumansAngina UnstableAngioplasty Balloon CoronaryInfusions IntravenousBlood CoagulationAgedBlood coagulation testDose-Response Relationship Drugmedicine.diagnostic_testHeparinUnstable anginabusiness.industryAnticoagulantThrombinAnticoagulantsPercutaneous coronary interventionHeparinHirudinsMiddle Agedmedicine.diseaseRecombinant ProteinsAnesthesiaPartial Thromboplastin TimeDrug MonitoringCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugPartial thromboplastin timeEuropean Heart Journal
researchProduct

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2…

2009

AbstractData from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyPopulationmacromolecular substancesGene mutationHemophilia AHemophilia BSeverity of Illness IndexBiochemistryArthroplastySettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineSeverity of illnessmedicineCoagulopathyHumansChildeducationRetrospective Studieseducation.field_of_studyHematologyhamophilia arthroplastybusiness.industryRetrospective cohort studyCell BiologyHematologyOdds ratioBlood Coagulation DisordersMiddle Agedmedicine.diseaseArthroplastySurgeryItalyJoint DiseasesbusinessAlgorithms
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

Clinical and echographical control protocol of haemarthrosis in haemophilia patients with inhibitors: evaluation of the efficacy of recombinant facto…

2008

Summary.  The intention of the ‘clinical and echographical protocol of evaluation the efficacy of recombinant activated factor VII in the haemarthrosis’ (EFFISEVEN protocol) was to provide an extensive study of the evolution of haemarthrosis, and second, of its repercussions on the degenerative process of joints. The clinical evaluation of haemarthroses and their evolution is based on a well-established methodology, although very few studies have sought to determine the correlation between pain, mobility and the objective data regarding the haemorrhage. We believe that it is necessary to unify criteria and that the EFFISEVEN protocol may contribute data that improve standards which, in turn…

Adultmedicine.medical_specialtyTime FactorsAdolescentObjective dataFactor VIIaHemophilia AHaemophiliaDrug Administration ScheduleYoung AdultClinical ProtocolsHemarthrosisActivated factor VIIHumansMedicineRange of Motion ArticularIntensive care medicineGenetics (clinical)UltrasonographyProtocol (science)Blood Coagulation Factor Inhibitorsbiologybusiness.industryObjective methodHematologyGeneral Medicinemedicine.diseaseArthralgiaBlood Coagulation FactorsRecombinant ProteinsPatient managementEuropeRecombinant factor VIIaQuality of Lifebiology.proteinPhysical therapyBlood Coagulation TestsbusinessClinical evaluationHaemophilia
researchProduct

VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY

2008

Summary.  Background: Combined vitamin K-dependent clotting factor (VKCF) deficiency type 2 (VKCFD2) is a rare bleeding disorder caused by mutated vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) gene. Methods and results: An Italian patient with moderate to severe bleeding tendency was genotyped, and found to be homozygous for the unique VKORC1 mutation (Arg98Trp) so far detected in VKCFD2. The activity levels of VKCFs were differentially reduced, and inversely related to the previously estimated affinity of procoagulant factor propeptides for the γ-carboxylase. The normal (factor IX) or reduced antigen levels (other VKCFs) produced a gradient in specific activities. Vitamin K su…

Adultmedicine.medical_specialtycoagulation factor levelsVitamin KProtein SMixed Function OxygenasesTissue factorchemistry.chemical_compoundInternal medicineVitamin K Epoxide ReductasesmedicineVKCFD2HumansFactor IXClotting factorCoagulation factor levels; Thrombin generation; Vitamin K supplementation; VKCFD2; VKORC1 mutation;biologyFactor VIIChemistryFactor XHomozygotevitamin K supplementationHematologyBlood Coagulation DisordersEndocrinologyTreatment OutcomeCoagulationthrombin generationImmunologyMutationbiology.proteinFemaleBlood Coagulation TestsVKCFD2 VKORC1 mutation coagulation factor levels thrombin generation vitamin K supplementationProtein Cmedicine.drugHalf-LifeVKORC1 mutation
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Association of Inflammation Markers with Impaired Insulin Sensitivity and Coagulative Activation in Obese Healthy Women

2003

Abstract Insulin resistance is associated with a low chronic inflammatory state. In this study we investigated the relationship between impaired insulin sensitivity and selected markers of inflammation and thrombin generation in obese healthy women. We examined 32 healthy obese women (body mass index ≥ 28), with normal insulin sensitivity (NIS, n = 14) or impaired insulin sensitivity (n = 18), and 10 nonobese women (body mass index < 25). Impaired insulin sensitivity patients had significantly higher levels of C-reactive protein (CRP), TGF-β1, plasminogen activator inhibitor-1 (PAI-1), activated factor VII (VIIa), and prothrombin fragment 1 + 2 (F1 + 2) compared with either control s…

Adultmedicine.medical_specialtyobesityEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryPopulationInflammationFactor VIIaBiologyBiochemistryEndocrinologyInsulin resistanceTransforming Growth Factor betaInternal medicineinsulin resistancePlasminogen Activator Inhibitor 1medicineHumansProtein PrecursorseducationBlood CoagulationPancreatic hormoneeducation.field_of_studyInsulinBiochemistry (medical)ThrombinMiddle Agedmedicine.diseaseObesityPeptide FragmentsC-Reactive ProteinEndocrinologyhemostasis; inflammation; insulin resistance; obesityinflammationhemostasisFemaleProthrombinmedicine.symptomBody mass indexPlasminogen activatorBiomarkers
researchProduct

Coagulation signaling and cancer immunotherapy.

2019

The last decades have delineated many interactions of the hemostatic system with cancer cells that are pivotal for cancer-associated thrombosis, angiogenesis and metastasis. Expanding evidence shows that platelets, the tissue factor pathway, and proteolytic signaling involving protease-activated receptors (PARs) are also central players in innate and adaptive immunity. Recent studies in immune-competent mice have uncovered new immune-evasive roles of coagulation signaling networks in the development and growth of different preclinical tumor models. Tumor-type specific PAR1 signaling facilitates the escape from immune surveillance by cytotoxic T cells. In addition, tumor-associated macrophag…

Angiogenesismedicine.medical_treatmentReceptors Proteinase-ActivatedMacrophage polarization030204 cardiovascular system & hematology03 medical and health sciencesMice0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsBlood CoagulationTumor microenvironmentInnate immune systembusiness.industryHematologyAcquired immune systemTumor antigen030220 oncology & carcinogenesisFactor XaCancer researchImmunotherapySignal transductionbusinessSignal TransductionThrombosis research
researchProduct